Table 3.
Comparison between low and normal-high FT4 groups in patients with COVID-19 presenting with NTI
| Low FT4 (n = 16) |
Normal-high FT4 (n = 134) |
P value | |
|---|---|---|---|
| Age, y, M (IQR) | 64.5 (41.75, 71.75) | 70 (62.25, 79.75) | 0.077 |
| Gender (female n, %) | 8 (50%) | 61 (45.52%) | 0.734 |
| Critical illness (n, %) | 9 (56.25%) | 57 (42.54%) | 0.296 |
| Mortality (n, %) | 8 (50%) | 34 (25.37%) | 0.038 |
| WBC, *10^9/L, M (IQR) | 10.35 (8.34, 26.87) | 10.92 (7.79, 16.65) | 0.455 |
| LC, *10^9/L, M (IQR) | 1.175 (0.72, 1.75) | 1.48 (0.98, 1.87) | 0.284 |
| CRP, mg/L, M (IQR) | 71.75 (37.65, 225.1) | 95.3 (42.675, 172.2) | 0.886 |
| Ferroprotein, ug/L, M (IQR) | 1782.2 (767.95, 7462.3) | 1221.9 (618.6, 2303.05) | 0.214 |
| PCT, ng/mL, M (IQR) | 0.97 (0.15, 8.56) | 0.17 (0.08, 0.87) | 0.021 |
| ALT, U/L, M (IQR) | 47 (23.75, 76) | 43 (21.25, 73.75) | 0.976 |
| AST, U/L, M (IQR) | 91.5 (38.25, 221.25) | 43 (26, 68.75) | 0.025 |
| ALB, g/L, M (IQR) | 32 (29.55, 34.55) | 35.7 (30.7, 39.3) | 0.277 |
| LDH, U/L, M (IQR) | 347 (248, 405) | 216.5 (177, 272.5) | 0.066 |
| CR, umol/L, M (IQR) | 124.5 (82.5, 214.5) | 87 (66.5, 114) | 0.029 |
| UREA, mmol/L, M (IQR) | 17.9 (5.73, 28.5) | 8.55 (5.7, 14.33) | 0.06 |
| cTnI, pg/mL, M (IQR) | 287 (8.7, 803.4) | 15.9 (6.4, 139) | 0.189 |
| D2D, ug/mL FEU, M (IQR) | 7.51 (1.85, 21) | 5.24 (1.39, 18.94) | 0.479 |
| FT3, pmol/L, M (IQR) | 2.36 (1.8, 2.795) | 2.69 (2.3625, 2.91) | 0.027 |
| FT4, pmol/L, M (IQR) | 10.55 (9.01, 11.69) | 16.75 (14.38, 18.46) | / |
| TSH, uIU/mL, M (IQR) | 1.82 (0.62, 2.15) | 0.897 (0.41, 1.79) | 0.235 |